NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., Goldhaber, S. Z., Gundabolu, K., Hendrie, P., Lee, A. I., Lee, J. T., Mann, J., McMahon, B., Millenson, M. M., Morton, C., Ortel, T. L., Ozair, S., Paschal, R., Shattil, S., Siddiqi, T., Smock, K. J., Soff, G., Wang, T., Williams, E., Zakarija, A., Hammond, L., Dwyer, M. A., Engh, A. M. 2018; 16 (11): 1289–1303


Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.

View details for DOI 10.6004/jnccn.2018.0084

View details for PubMedID 30442731